In vivo and in vitro experiments confirmed that a BCL2 inhibitor can induce the apoptosis of SCLC cell lines with high BCL2 levels, indicating that a BCL2 inhibitor may be effective for treating the ASCL1 subtype of SCLC [92]. The gene discussed is ASCL1; the disease is small cell lung carcinoma.